4/A: REGENXBIO CEO Awarded Corrected Stock Options Grant

REGENXBIO's CEO, Curran Simpson, received a corrected stock option grant of 478,606 shares, amending a previous filing due to a share calculation error.

Summary

• This document is an amended SEC Form 4, filed by REGENXBIO's CEO, Curran Simpson.
• The amendment corrects a previous filing from January 6, 2025, which misreported the number of stock options granted to Mr. Simpson.
• The corrected number of stock options granted is 478,606, an increase from the previously reported 476,606.
• The stock options have an exercise price of $7.86.
• 25% of the options will vest after 12 months of continuous service, with the remainder vesting monthly over the following 36 months starting January 2, 2026.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previous error, which is a neutral event. The vesting schedule is a positive for long-term alignment of interests.

Positives

• The correction ensures accurate reporting of executive compensation.
• The vesting schedule incentivizes long-term service from the CEO.

Risks

• There is a risk of further errors in reporting if the company does not improve its internal controls.
• The vesting schedule could be impacted if the CEO leaves the company before the options fully vest.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This type of filing is standard for publicly traded companies when reporting changes in beneficial ownership by executives. It is common for companies to grant stock options as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The vesting schedule of 25% after one year and the remainder over the following 36 months is a fairly standard practice.
• The exercise price of $7.86 is specific to REGENXBIO and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• Shareholders will benefit from accurate reporting of executive compensation.
• The vesting schedule aligns the CEO's interests with the long-term performance of the company.

Key Dates

Keywords

stock options, executive compensation, SEC Form 4, REGENXBIO, vesting, Curran Simpson